Astra antibody cocktail fails to prevent Covid-19 symptoms in large trial
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
FRIDAY, MAY 20, 2022
FRIDAY, MAY 20, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Astra antibody cocktail fails to prevent Covid-19 symptoms in large trial

Coronavirus chronicle

Reuters
15 June, 2021, 01:15 pm
Last modified: 15 June, 2021, 06:06 pm

Related News

  • China relaxes some Covid test rules for US, other travellers
  • New York Times pauses return to office for workers
  • S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • RMCH shuts down its corona unit

Astra antibody cocktail fails to prevent Covid-19 symptoms in large trial

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms

Reuters
15 June, 2021, 01:15 pm
Last modified: 15 June, 2021, 06:06 pm
Syringes with AstraZeneca coronavirus disease (COVID-19) vaccines are prepared in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo
Syringes with AstraZeneca coronavirus disease (COVID-19) vaccines are prepared in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo

AstraZeneca  said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms.

The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product's fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

Targeted alternatives

AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

Similar therapies developed by rivals Regeneron and Eli Lilly have been approved by US regulators for treating unhospitalised Covid patients.

European regulators have also authorised Regeneron's therapy and are reviewing those developed by partners GlaxoSmithKline and Vir Biotechnology as well as by Lilly and Celltrion.

Regeneron is also seeking US authorisation for its therapy as a preventative treatment. 

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to Covid-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its Covid-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

AstraZeneca also said on Tuesday it was in talks with the US government on "next steps" regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.

The full results will be submitted for publication in a peer-reviewed medical journal, the company said.

Top News / World+Biz

AstraZeneca / COVID-19 / patients

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • What needs to be done now?
    What needs to be done now?
  • File photo of Dr Debapriya Bhattacharya. Picture: CPD
    Fiscal consolidation is a way out
  • Safety net needs to be expanded by minimising corruption 
    Safety net needs to be expanded by minimising corruption 

MOST VIEWED

  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says

Related News

  • China relaxes some Covid test rules for US, other travellers
  • New York Times pauses return to office for workers
  • S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • RMCH shuts down its corona unit

Features

Sketch: TBS

'Food inflation is an unavoidable consequence of currency devaluation'

17h | Interviews
The open-browser-tabs question also tells an interviewer how much of an internet native the job applicant might be. Photo: Noor-a-Alam

The best question to ask a job applicant

17h | Pursuit
Illustration: TBS

Ugly business: Politics in workplace

16h | Pursuit
Illustration: TBS

‘Do you have insurance?’: Life of a life insurance agent

19h | Panorama

More Videos from TBS

Putin's strategies to face Nato

Putin's strategies to face Nato

6h | Videos
How many countries have nuclear weapons and how many are there?

How many countries have nuclear weapons and how many are there?

6h | Videos
Dengue fever is rising, so beware

Dengue fever is rising, so beware

6h | Videos
How a university teacher and PHD holder become farmer

How a university teacher and PHD holder become farmer

11h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

5
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab